Surgical treatment of peritoneal carcinomatosis from gastric cancer
- PMID: 22778938
- PMCID: PMC3388312
- DOI: 10.1155/2012/405652
Surgical treatment of peritoneal carcinomatosis from gastric cancer
Abstract
Peritoneal carcinomatosis from gastric cancer is considered a fatal disease with limited treatment options. Recent advances in the understanding of the disease process, systemic chemotherapy, and application of cytoreductive surgery and hyperthermic chemoperfusion have shown promising results in the management of this difficult disease. Novel therapies such as extensive intraperitoneal lavage and intraperitoneal targeted agents are being applied in the management of this disease. We review the current literature in this field and describe the rationale behind some of these advances.
Figures
Similar articles
-
Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis.Cancer. 2010 Aug 15;116(16):3756-62. doi: 10.1002/cncr.25116. Cancer. 2010. PMID: 20564081
-
Treatment of Peritoneal Dissemination in Stomach Cancer Patients With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Rationale and Design of the PERISCOPE Study.JMIR Res Protoc. 2017 Jul 13;6(7):e136. doi: 10.2196/resprot.7790. JMIR Res Protoc. 2017. PMID: 28705789 Free PMC article.
-
[Cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion for peritoneal carcinomatosis caused by recurrent inflammatory myofibroblastic sarcoma: a case report and review of the literature].Orv Hetil. 2006 Jan 29;147(4):147-58. Orv Hetil. 2006. PMID: 16515023 Review. Hungarian.
-
Rationale for hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment or prevention of peritoneal carcinomatosis.Acta Chir Belg. 2004 Aug;104(4):377-83. Acta Chir Belg. 2004. PMID: 15469146 Review.
-
Timing of Systemic Chemotherapy in Patients With Colorectal Peritoneal Carcinomatosis Treated With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.Dis Colon Rectum. 2017 May;60(5):477-487. doi: 10.1097/DCR.0000000000000774. Dis Colon Rectum. 2017. PMID: 28383447
Cited by
-
Hyperthermic Intraperitoneal Chemotherapy plus Intravenous Chemotherapy of Paclitaxel with or without Sintilimab in Gastric Cancer: A Comparative Study.J Oncol. 2022 Feb 22;2022:3054485. doi: 10.1155/2022/3054485. eCollection 2022. J Oncol. 2022. PMID: 35242186 Free PMC article.
-
Metastatic adenocarcinomas of the stomach or esophagogastric junction (UICC stage IV) are not always a palliative situation: a retrospective analysis.World J Surg. 2014 Feb;38(2):419-25. doi: 10.1007/s00268-013-2293-1. World J Surg. 2014. PMID: 24146196
-
PRL-3 promotes gastric cancer peritoneal metastasis via the PI3K/AKT signaling pathway in vitro and in vivo.Oncol Lett. 2018 Jun;15(6):9069-9074. doi: 10.3892/ol.2018.8467. Epub 2018 Apr 11. Oncol Lett. 2018. PMID: 29805638 Free PMC article.
-
Educational Review: Updates on Therapeutic Strategies for Gastric Cancer with Peritoneal Metastasis.Ann Surg Oncol. 2025 May;32(5):3672-3687. doi: 10.1245/s10434-025-17069-3. Epub 2025 Feb 27. Ann Surg Oncol. 2025. PMID: 40016614 Review.
-
MicroRNA-760 acts as a tumor suppressor in gastric cancer development via inhibiting G-protein-coupled receptor kinase interacting protein-1 transcription.World J Gastroenterol. 2019 Dec 7;25(45):6619-6633. doi: 10.3748/wjg.v25.i45.6619. World J Gastroenterol. 2019. PMID: 31832002 Free PMC article.
References
-
- Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. Journal of Clinical Epidemiology. 2003;56(1):1–9. - PubMed
-
- Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. Ca-A Cancer Journal for Clinicians. 2006;56(2):106–130. - PubMed
-
- Yonemura Y, Endou Y, Sasaki T, et al. Surgical treatment for peritoneal carcinomatosis from gastric cancer. European Journal of Surgical Oncology. 2010;36(12):1131–1138. - PubMed
-
- Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. Journal of Clinical Oncology. 2002;20(8):1996–2004. - PubMed
-
- Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine. 2006;355(1):11–20. - PubMed
LinkOut - more resources
Full Text Sources